3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Hematologic Neoplasms
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Myelodysplastic Syndromes
3
Leukemia, Myeloid, Acute
3
beta-Thalassemia
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Hodgkin Disease
2
Graft vs Host Disease
2
Anemia, Refractory, with Excess of Blasts
2
Virus Diseases
1
Thalassemia
1
Primary Myelofibrosis
1
Non-Malignant Neoplasm
1
Neurofibromatosis 1
1
Neoplasm, Residual
1
Myeloproliferative Disorders
1
Leukemia, Myelomonocytic, Juvenile
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, B-Cell
1
Influenza, Human
1
Fanconi Anemia
1
Cytopenia
1
Chromosome Aberrations
1
Chromosome 7, monosomy
1
Anemia, Sickle Cell
1
Interventions
Cyclophosphamide
7
acalabrutinib
4
pirtobrutinib
3
fludarabine
3
Rituximab
3
fludarabine phosphate
2
Vincristine
2
Melphalan
2
Doxorubicin
2
thymoglobulin
1
obinutuzumab
1
idecabtagene vicleucel
1
ibrutinib
1
Stem Cell Transplantation
1
Prednisone
1
Prednisolone
1
Mycophenolic Acid
1
Mesna
1
Immunotherapy, Adoptive
1
Filgrastim
1
Diet
1
Bone Marrow Transplantation
1
ARQ531
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Leukemia, B-Cell
×
thymoglobulin
×
Clear all
NCT03852407
2022-10-12
HLA
University of Liege
Phase 2
Recruiting
114 enrolled